{"result": "(\"entity\"<|>HOSPITAL SANTIAGO APÓSTOL<|>ORGANIZATION<|>Hospital Santiago Apóstol de Vitoria was operational from 1994 to 2005, providing medical services in the region.)\n##\n(\"entity\"<|>HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLES<|>ORGANIZATION<|>Hospital Clínico Universitario Lozano Blesa de Zaragoza operated from 2005 to 2007, offering healthcare services.)\n##\n(\"entity\"<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>ORGANIZATION<|>Clínica Universidad de Navarra is a medical institution where the individual has worked since 2007, focusing on endocrinology and nutrition.)\n##\n(\"entity\"<|>UNIVERSIDAD DE ZARAGOZA<|>ORGANIZATION<|>Universidad de Zaragoza is an educational institution where the individual served as an associate professor in Health Sciences.)\n##\n(\"entity\"<|>UNIVERSIDAD DE NAVARRA<|>ORGANIZATION<|>Universidad de Navarra is an educational institution where the individual is currently an associate professor of Endocrinology.)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes is a primary area of research for the individual, focusing on type 1 diabetes and related treatments.)\n##\n(\"entity\"<|>NEFROPATÍA DIABÉTICA<|>EVENT<|>Diabetic nephropathy is a significant area of research for the individual, related to diabetes complications.)\n##\n(\"entity\"<|>RIESGO CARDIOVASCULAR<|>EVENT<|>Cardiovascular risk is a key research area for the individual, particularly in relation to diabetes.)\n##\n(\"entity\"<|>AVANCES EN DIABETOLOGÍA<|>ORGANIZATION<|>Avances en Diabetología is a journal where the individual served as an associate editor from 2011 to 2014.)\n##\n(\"entity\"<|>ENDOCRINOLOGÍA, DIABETES Y NUTRICIÓN<|>ORGANIZATION<|>Endocrinología, Diabetes y Nutrición is a journal where the individual was deputy editor from April 2017 to April 2019.)\n##\n(\"entity\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Spanish Society of Endocrinology and Nutrition is a professional organization where the individual has been involved in education programs.)\n##\n(\"entity\"<|>SEEN<|>ORGANIZATION<|>SEEN is the Spanish Society of Endocrinology and Nutrition, where the individual was elected president in 2019.)\n##\n(\"relationship\"<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>HOSPITAL SANTIAGO APÓSTOL<|>The individual worked at Hospital Santiago Apóstol before joining Clínica Universidad de Navarra<|>5)\n##\n(\"relationship\"<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLES<|>The individual worked at Hospital Clínico Universitario Lozano Blesa before joining Clínica Universidad de Navarra<|>5)\n##\n(\"relationship\"<|>UNIVERSIDAD DE ZARAGOZA<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual was an associate professor at Universidad de Zaragoza before becoming an associate professor at Clínica Universidad de Navarra<|>5)\n##\n(\"relationship\"<|>UNIVERSIDAD DE NAVARRA<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual is currently an associate professor at Universidad de Navarra while working at Clínica Universidad de Navarra<|>8)\n##\n(\"relationship\"<|>DIABETES<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual conducts research on diabetes at Clínica Universidad de Navarra<|>7)\n##\n(\"relationship\"<|>NEFROPATÍA DIABÉTICA<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual researches diabetic nephropathy at Clínica Universidad de Navarra<|>7)\n##\n(\"relationship\"<|>RIESGO CARDIOVASCULAR<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual studies cardiovascular risk related to diabetes at Clínica Universidad de Navarra<|>7)\n##\n(\"relationship\"<|>AVANCES EN DIABETOLOGÍA<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual was an associate editor for Avances en Diabetología while conducting research at Clínica Universidad de Navarra<|>5)\n##\n(\"relationship\"<|>ENDOCRINOLOGÍA, DIABETES Y NUTRICIÓN<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual was deputy editor for Endocrinología, Diabetes y Nutrición while working at Clínica Universidad de Navarra<|>5)\n##\n(\"relationship\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual is involved in the Spanish Society of Endocrinology and Nutrition while working at Clínica Universidad de Navarra<|>5)\n##\n(\"relationship\"<|>SEEN<|>CLÍNICA UNIVERSIDAD DE NAVARRA<|>The individual was elected president of SEEN while working at Clínica Universidad de Navarra<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: el Hospital Santiago Apóstol de\n            Vitoria (1994-2005) y en el Hospital Clínico Universitario Lozano Blesa de Zaragoza\n            (2005-2007).\n            Desde septiembre de 2007 a junio de 2018 ha sido consultor del Departamento de\n            Endocrinología y Nutrición de la Clínica Universidad de Navarra y responsable del\n            Área de Diabetes. Desde junio de 2018 es el director del Departamento de Endocri-\n            nología y Nutrición de la Clínica Universidad de Navarra. Tutor de residentes desde\n            noviembre 2016 hasta agosto 2018.\n            Ha ejercido como profesor asociado en Ciencias de la Salud de la Facultad de\n            Medicina de la Universidad de Zaragoza y actualmente es profesor asociado\n            de Endocrinología en la Facultad de Medicina de la Universidad de Navarra (2007-).\n            Sus áreas de investigación principales son diabetes tipo 1 y tratamiento con célu-\n            las mesenquimales, nefropatía diabética y diabetes y riesgo cardiovascular.\n            Ha sido y es investigador principal e investigador colaborador de distintos proyec-\n            tos de investigación, fundamentalmente relacionados con el área de diabetes. Ha\n            sido editor asociado de la revista Avances en Diabetología (2011-2014) y Endocri-\n            nología y Nutrición (2014-2017). Desde abril de 2017 hasta abril de 2019 ha sido\n            editor jefe adjunto de la revista Endocrinología, Diabetes y Nutrición.\n            Ha pertenecido a la junta de la Sociedad Española de Endocrinología y Nutrición\n            como responsable de los programas de docencia para residentes y formación\n            continuada de especialistas. Asimismo, es miembro de los grupos de trabajo\n            de Diabetes, de la Sociedad Española de Endocrinología y Nutrición, del Grupo de\n            Consensos      de  la Sociedad Española        de   Diabetes y    del Grupo de lípidos de la\n            Sociedad Española de Endocrinología y Nutrición.\n            Presidente electo de la SEEN (2019).\n---\n                                                                                                                                                                                     OBESIDAD,               LÍPIDOS                      8\n                                                                                                                                                         Y TRASTORNOS ELECTROLÍTICOS\n\n\n\n     8.3 Lípidos                                                                                                     2.  Hipercolesterolemia poligénica.              La mayoría de las hipercolesterolemias moderadas\n                                                                                                                         [niveles de colesterol plasmático entre 240 y 350 mg/dl (6,2-9,1 mmol/l)] son de origen\n                                                                                                                         poligénico; esto quiere decir que intervienen números genes que interactúan con el me-\n        24     ¿Cuál de las siguientes opciones es falsa en relación con las hipercolesterolemias?                       dio ambiente y provocan la hipercolesterolemia, y pueden ser responsables tanto de la\n                                                                                                                         producción excesiva como de la disminución del catabolismo de las LDL. Se presentan\n               A. El alirocumab es un nuevo fármaco que reduce drásticamente los niveles de colesterol LDL.              niveles normales de triglicéridos y HDL colesterol. No existen xantomas.\n               B. En la hipercolesterolemia homocigota, los niveles de colesterol LDL suelen ser superiores          3.  Déficit familiar de apolipoproteína B-100. Este trastorno autosómico dominante es una\n                   a 500 mg/dl.                                                                                          fenocopia de la hipercolesterolemia familiar y se debe a una mutación sin sentido en el\n               C. Los xantomas palmares suelen aparecer en la hiperlipidemia familiar combinada.                         aminoácido 3.500 que disminuye la afinidad de la LDL por el receptor de LDL. La preva-\n                                                                                                                         lencia y manifestaciones de las formas heterocigotas y homocigotas son similares a las\n               D.  En pacientes con muy alto riesgo cardiovascular (diabetes y enfermedad cardiovascular),               producidas por mutaciones del receptor de LDL.\n                   el tratamiento debe prescribirse para tener niveles de colesterol LDL inferiores a 70 mg/dl.      La dislipidemia constituye uno de los factores de riesgo cardiovascular más íntimamen-\n                                                                                                                     te ligados con la enfermedad cardiovascular, primera causa de muerte prematura en el\n               COMENTARIO                                                                                            mundo, y fue responsable en el año 2011 de un total de casi 17 millones de fallecimientos.\n               Un xantoma es una afección cutánea caracterizada por la formación de placas o nódulos                 Por ello, es importante conseguir un adecuado control del colesterol LDL, con objetivos de\n               más o menos planos, amarillos, ligeramente elevados y de tamaño diverso. Generalmente                 colesterol LDL      < 70   mg/dl en caso de existencia de enfermedad cardiovascular previa y\n               dependen de una afectación del hígado o de un trastorno metabólico de los lípidos. Se                 diabetes. Para ello, disponemos de f\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}